Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership (NYSE:BMY)

Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield.